FGFR2‐RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Cancer"
DOI: 10.1002/ijc.35302
Abstract: Overcoming luminal breast cancer (BrCa) progression remains a critical challenge for improved overall patient survival. RUNX2 has emerged as a protein related to aggressiveness in triple‐negative BrCa, however its role in luminal tumors remains elusive.… read more here.
Keywords: brca; progression; fgfr2 runx2; tumor ... See more keywords
FGFR2 in the Development and Progression of Cutaneous Squamous Cell Cancer
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23835
Abstract: Cutaneous squamous cell carcinoma (cSCC) is an increasingly common malignancy of the skin and the leading cause of death from skin cancer in adults over the age of 85. Fibroblast growth factor receptor 2 (FGFR2)… read more here.
Keywords: cancer; development; cutaneous squamous; squamous cell ... See more keywords
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-52991-8
Abstract: FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (GAs) in… read more here.
Keywords: fgfr2 signalling; activated fgfr2; selection intrahepatic; intrahepatic cholangiocarcinoma ... See more keywords
Oligodendrocyte‐specific deletion of FGFR2 ameliorates MOG35‐55‐induced EAE through ERK and Akt signalling
Sign Up to like & getrecommendations! Published in 2020 at "Brain Pathology"
DOI: 10.1111/bpa.12916
Abstract: Fibroblast growth factors (FGFs) and their receptors (FGFRs) are involved in demyelinating pathologies including multiple sclerosis (MS). In our recent study, oligodendrocyte‐specific deletion of FGFR1 resulted in a milder disease course, less inflammation, reduced myelin… read more here.
Keywords: oligodendrocyte specific; specific deletion; eae; fgfr2 ... See more keywords
Abstract 2647: Novel FGFR2 biparatopic antibodies for the treatment of cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2647
Abstract: Translocations involving Fibroblast Growth Factor Receptor 2 (FGFR2) are found in up to 45% of Intrahepatic Cholangiocarcinoma (ICC). Treatment of patients bearing FGFR2 fusions with FGFR kinase inhibitors induces tumor regressions, though response rate and… read more here.
Keywords: fusion; fgfr2; growth; biparatopic antibodies ... See more keywords
Abstract 1968: Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1968
Abstract: Fibroblast growth factor receptor 2 (FGFR2) is a clinically validated target and frequently altered in many solid tumors. The resulting oncogenic driver alterations often drive multiple solid tumors. Therefore, targeting FGFR2 has broad therapeutic potential.… read more here.
Keywords: potent selective; fgfr2 inhibitor; fgfr2 driven; selective fgfr2 ... See more keywords
FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway
Sign Up to like & getrecommendations! Published in 2018 at "Cellular Physiology and Biochemistry"
DOI: 10.1159/000494590
Abstract: Background/Aims: Fibroblast growth factor receptor 2 (FGFR2) has attracted considerable interest as a therapeutic target in gastric cancer (GC). There is growing evidence to suggest that the bioavailability of the potent pro-tumor function of FGFR2… read more here.
Keywords: pi3k akt; fgfr2 tsp4; expression; fgfr2 ... See more keywords
FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Translational Medicine"
DOI: 10.1186/s12967-021-03079-8
Abstract: Background Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied… read more here.
Keywords: poorly cohesive; fgfr2; gene; fgfr2 inhibitors ... See more keywords
PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.516
Abstract: 516 Background: Infigratinib (BGJ398), an oral inhibitor of fibroblast growth factor receptor (FGFR)1-3 with demonstrated clinical activity and a manageable adverse event profile in a phase 2 study in patients with previously treated, unresectable or… read more here.
Keywords: fgfr2; trial; gem cis; phase ... See more keywords
A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps3171
Abstract: TPS3171 Background: Genetic alterations in fibroblast growth factor receptors 2 and 3 ( FGFR2/3 ) occur in nearly all cancer types. FGFR2 fusions and rearrangements occur in up to 10-15% of intrahepatic cholangiocarcinomas (iCCA) and… read more here.
Keywords: solid tumors; dose escalation; cgt4859; fgfr2 ... See more keywords
Somatic FGFR2 is required for germ cell maintenance in the mouse ovary.
Sign Up to like & getrecommendations! Published in 2023 at "Endocrinology"
DOI: 10.1210/endocr/bqad031
Abstract: During sex determination in the mouse, Fibroblast growth factor 9 (FGF9) signals through the fibroblast growth factor receptor 2c isoform (FGFR2c) to trigger Sertoli cell and testis development from 11.5 days post coitum (dpc). In… read more here.
Keywords: germ cell; fgfr2 required; cell; fgfr2 ... See more keywords